Skip to main content

How is Sotyktu given / administered?

Medically reviewed by Leigh Ann Anderson, PharmD. Last updated on Jan 19, 2023.

Official answer


Sotyktu (pronounced “soh-tik-too”) is given as an oral tablet once per day, with or without food. Take it at about the same time each day. Do not crush, cut, or chew the tablets. Sotyktu is used in adults at least 18 years of age. It is not known if it is safe and effective in children.

Your dermatologist will determine if you need any laboratory tests, or a test for tuberculosis (TB), before treatment starts.

Do not take Sotyktu if  you are allergic to deucravacitinib or any of the inactive ingredients or excipients in this medicine (listed in the Medication Guide). Your pharmacist can provide you with a Medication Guide if you do not have one. If you have severe liver disease, you may not be able to use this medicine, so talk to your doctor before you start treatment.

Sotyktu (deucravacitinib) is an oral treatment used to treat adults with moderate-to-severe plaque psoriasis who may benefit from systemic therapy (injections or pills) or phototherapy (specialized type of UV light).

Take Sotyktu exactly as your healthcare provider tells you to take it. Be sure to tell your healthcare providers and pharmacist about all the medicines you take,  including prescription, over-the-counter (OTC) medicines, vitamins, and herbal or dietary supplements.

How do I get Sotyktu?

Sotyktu will be mailed to you from a specialty pharmacy after your doctor prescribes it. You will not usually pick it up from your regular pharmacy.

  • Specialty medicines are typically expensive medicines. The specialty pharmacy can help you with medication insurance, access to the medicine, answer any of your questions, and help monitor for the drug’s safety and effectiveness, if needed.
  • The specialty pharmacy can also help you set up your refills so you’ll never miss a dose.
  • You may be eligible for a free trial of medicine if you are using Sotyktu for the first time. Speak to your healthcare provider for more information.
  • Sotyktu is manufacturer by Bristol-Myers Squibb and was first approved in September 2022.

Learn more: How much does Sotyktu cost?

Related questions

Does Sotyktu have a Black Box Warning?

No, the product labeling for Sotyktu does NOT contain a Boxed Warning. It does contain important Warnings and Precautions, such as:

  • Hypersensitivity (serious or life-threatening allergic reactions) and angioedema
  • Increase risk of Infections
  • Tuberculosis
  • Rhabdomyolysis (serious muscle problems) and elevated CPK (an enzyme in your blood that may signal liver damage)
  • Laboratory changes (for example: serum triglycerides, liver enzymes)
  • Avoiding use with live vaccines
  • Potential risks related to JAK Inhibition

Sotyktu is a tyrosine kinase 2 (TYK2) inhibitor, part of the Janus kinase (JAK) family. It is not known whether TYK2 inhibition may be associated with side effects of JAK inhibition such as increased risk of death. This occurred with other medicines in older patients with heart disease who were using a JAK inhibitor to treat rheumatoid arthritis. Sotyktu is NOT approved for use in rheumatoid arthritis.

This is not all the information you need to know about Sotyktu (deucravacitinib) for safe and effective use and does not take the place of your doctor’s directions. Review the full product information and discuss any questions you have with your doctor or other health care provider.


Read next

Related medical questions

Drug information

Related support groups